Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem

A big dividend can’t hide the growth problem at Pfizer PFE +0.64% ▲ , one of the world’s largest pharmaceutical companies. Pfizer has seen its stock rise more than 16% over the past six months, outperforming the broader market that declined by over 2% during the same period. However, despite that relative strength, I remain bearish on the stock.

End of Quarter Sale - 50% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

In my view, the company faces a multi-year growth challenge driven by looming patent expirations, a poorly timed pipeline, and limited near-term catalysts — issues that a dividend yield of around 6.25% alone cannot offset.

A Looming Revenue Cliff That Is Hard to Ignore

The biggest issue Pfizer is facing is what I refer to as a structural revenue cliff. By 2030, roughly $15–20 billion of annual revenue — around a third of its current base — is expected to face loss of exclusivity. Key drugs like Eliquis, Ibrance, Xtandi, and Vyndaqel are all approaching patent expiration windows over the next few years.

This is not just a normal patent cycle — it is a concentrated hit that could drive a prolonged period of declining revenue and earnings. Pfizer could see revenue contract at roughly a 5% annual rate through the end of the decade, with earnings falling even faster. That would make it one of the weakest growth profiles among large-cap pharmaceutical peers.

The core issue is not just the loss of revenue, but the lack of visible replacements. Unlike past cycles when new blockbuster drugs were ready to step in, Pfizer’s pipeline appears misaligned in timing, leaving a gap of several years where earnings could remain under pressure.

Pipeline Potential Exists — but Arrives Too Late

Pfizer is not lacking in pipeline depth. The company has multiple promising assets across oncology, immunology, and obesity. The problem is that most of these programs are unlikely to meaningfully contribute until 2027–2030, precisely when the patent cliff hits hardest.

This timing mismatch creates a visibility problem. Investors typically assign value to pipelines when there is clearer data and a nearer path to commercialization. In Pfizer’s case, many of the key programs are still in mid- to late-stage trials, with pivotal data years away. That makes it difficult for the market to price in future growth with confidence.

There are some encouraging early signals. For example, recent Phase 2 data in breast cancer and immunology show potential, but these are still early-stage developments. Even optimistic scenarios suggest that meaningful revenue contribution from these programs is unlikely in the next two to three years. In the meantime, the company is left navigating a period of declining core earnings.

The Obesity Opportunity Looks Structurally Disadvantaged

One of Pfizer’s most talked-about growth opportunities is its push into the obesity market. However, here too, the company appears to be playing catch-up.

Its leading candidate, MET-097i, has demonstrated 12.3% weight loss in trials, below the levels achieved by leading competitor therapies. More importantly, the company is entering the market three to five years behind established leaders, who have already built significant manufacturing capacity, physician adoption, and reimbursement frameworks.

In a market where scale and first-mover advantage matter, that delay is critical. Competitors have already committed tens of billions of dollars to manufacturing and distribution, creating a moat that is difficult to overcome. Pfizer may still capture a portion of the market, but it is unlikely to emerge as a dominant player.

The Dividend Provides Support — but Not a Solution

One of the main arguments in favor of Pfizer is its dividend yield of around 6.25%. That is attractive, particularly in a volatile market environment, and it likely provides some downside support for the stock.

However, income alone is not enough to justify an investment if the underlying business is facing structural decline. In Pfizer’s case, the dividend is supported by a payout ratio that has raised some concerns, especially as earnings come under pressure. If revenue and profits decline as expected, maintaining the current dividend could become increasingly challenging.

More importantly, a high dividend yield often reflects low growth expectations. Investors may be getting paid to wait, but they are also accepting the risk that capital appreciation will remain limited. In my view, that trade-off is not particularly compelling when compared to other pharmaceutical companies with stronger growth visibility.

**Wall Street’s View **

According to TipRanks, Pfizer has a Moderate Buy rating, with eight Buy, 12 Hold, and two Sell ratings. The average price target of $29.07 implies only about 3.6% upside from current levels.

Conclusion

I remain bearish on Pfizer because I believe the company is facing a difficult transition period that is not fully offset by its pipeline or dividend. The combination of a significant revenue cliff, delayed pipeline contributions, and a late entry into key growth markets, such as obesity, creates a challenging setup for the next several years.

While the stock’s high yield may attract income-focused investors, I see limited potential for meaningful near-term upside. Until there is clearer visibility into sustainable growth beyond the patent cliff, I believe Pfizer remains a stock to approach with caution.

Disclaimer & DisclosureReport an Issue